Rituximab for the treatment of corticosteroid - refractory pemphigus vulgaris with oral and skin manifestations

Journal of Oral Pathology and Medicine

Volumn 40, Issue 8, 2011, Pages 616-620

  Craythorne, Emma ^a   Du Viver, Anthony ^a   Mufti, Ghulam J ^a   Warnakulasuriya, Saman ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Bullous lesions; Oral mucosa

Indexed keywords

CD20 ANTIBODY; CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG RESPONSE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; MALE; MOUTH DISEASE; OUTCOME ASSESSMENT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY PEMPHIGUS VULGARIS; SKIN DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MOUTH DISEASES; PEMPHIGUS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; TREATMENT OUTCOME;

EID: 79960915333     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01017.x     Document Type: Article

References (20)

1. Bystryn J-C, Rudolph JL. Pemphigus. Lancet 2005; 366: 61-73.
2. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116: 1159-66.
3. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in Pemphigus Vulgaris. J Invest Dermatol. 2008; 128: 2850-8.
4. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-37.
5. Jiao D, Natow S, Bystryn J-C. Treatment of pemphigus with IVIg. J Am Acad Dermatol 2002; 47: 358-63.
6. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate moftetil. Arch Dermatol 2003; 139: 739-43.
7. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 17-24.
8. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
9. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with Rituximab report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-8.
10. Dupuy A, Viguier M, Be'dane C, et al. Treatment of refractory pemphigus vulgaris With Rituximab (Anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91-6.
11. Kimby E. Tolerability and safety of rituximab. Cancer Treat Rev 2005; 31: 456-73.
12. Lu TY-T, Jonsdottir T, van Vollenhoven RF, Isenberg DA Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 2008;67:1493-4. doi:.
13. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675-82.
14. Vugmeyster Y, Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effects of IgG. Int Immunopharmacol 2004; 4: 1117-24.
15. Leandro MJ, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20.
16. Albert D, et al. Variability in the biological response to anti CD20 B-cell depletion in SLE. Ann Rheum Dis 2008; 67: 142-4.
17. Manshouri T, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukaemia and is of prognostic significance. Blood 2003; 101: 2507-13.
18. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620-5.
19. Assous N, Gossec L, Dieudé P, et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008; 35: 31-420.
20. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-91.